News|Slideshows|December 12, 2018

Icosapent Ethyl Effective in Lowering Cardiovascular Risk

What impact does this highly purified form of omega-3 fatty acid have on cardiovascular events? Authors of the REDUCE-IT trial sought to find out.

What effect does icosapent ethyl, a highly purified and stable form of fish oil, have on cardiovascular events? That is the question authors the REDUCE-IT trial sought to answer. What did they find? And how will their results impact future research and clinical practice? Click through the slideshow below to find out.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Icosapent Ethyl Effective in Lowering Cardiovascular Risk

Related Content

Intensive Blood Pressure Control in Primary Care May Lower Dementia Risk

FDA Expands Tirzepatide Label for Cardiovascular Risk Reduction in Type 2 Diabetes

Physical Activity May Reduce Stroke and Mortality Risk in Persons With Atrial Fibrillation

Nearly 80% of Young Adults Show Signs of CKM Syndrome, Study Finds

Dementia Prevention Research Expands Beyond Traditional Vascular Risk Factors

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Kansas Society of Clinical Oncology

EyeCon 2026

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

27th Annual International Lung Cancer Congress®

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

The Optometry Meeting in Anaheim

Jersey City Psychiatry

Join Us at The Pathology Meeting in Las Vegas

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Join Us at The Pathology Meeting in Las Vegas

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

IgAN Case Files: Real Conversations, Evolving Evidence

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Louisiana Oncology Society

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

20th Annual New York Lung Cancers Symposium®

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

ISGIO 2025: Advanced-Stage Colorectal Cancer

ISGIO 2025: Hepatobiliary Cancers

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

ISGIO 2025: Early-Stage Colorectal Cancer

ISGIO 2025: Esophageal and Gastric Cancer

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

4th Annual International Congress on Pediatric Oncology

ISGIO 2025: Pancreatic and Neuroendocrine Tumors

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Burst CME™ in Gaucher Disease: Patient Evaluation and Management

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Burst CME™: Optimal Management of Complications of Sickle Cell Disease

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Burden of Sickle Cell Disease

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification